February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
9 citations,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
June 2006 in “American Journal of Epidemiology” Long-term diabetes is linked to lower prostate cancer risk.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
3 citations,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
67 citations,
January 1987 in “The Journal of urology/The journal of urology” New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.
1 citations,
January 2020 in “Egyptian Journal of Dermatology and Venereology” Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.
February 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.
21 citations,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
93 citations,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
54 citations,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
29 citations,
October 2020 in “eLife” Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.
24 citations,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
20 citations,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
20 citations,
February 2009 in “Chemistry & Biodiversity” Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.
16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
16 citations,
September 1964 in “The journal of investigative dermatology/Journal of investigative dermatology” New compounds can block testosterone effects in rats and might help treat conditions like prostate cancer and acne.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
15 citations,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
15 citations,
January 2009 in “International Journal of Andrology” Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.
14 citations,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
11 citations,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
11 citations,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
9 citations,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
7 citations,
August 2006 in “Maturitas” Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.